top of page

Another Hawaii Senate Committee OKs Bill To Support Clinical Research On Psychedelic-Assisted Therapy

  • Writer: Bob Marley
    Bob Marley
  • Feb 20, 2025
  • 3 min read

A second Hawaii Senate committee has advanced a proposal that would create a special fund to support clinical research into psychedelic-assisted treatment using substances such as psilocybin and MDMA, both of which have been granted “breakthrough therapy” status by the U.S. Food and Drug Administration (FDA).

The bill, SB 1042, from Sen. Chris Lee (D), would establish a state “mental health emerging therapies special fund,” which could be used to subsidize clinical trials, establish public-private research partnerships and eventually develop state programs around patient access for “compassionate use.”

On Wednesday, the Senate Ways and Means Committee reported the bill without amendments or objection on a unanimous 13-0 vote.

As defined in the text of the measure, “emerging therapies” refers to psychedelic or entactogenic substances that are either approved by the FDA or under Hawaii state law as well as compounds undergoing FDA-approved clinical trials.

“Compassionate use,” meanwhile, would mean “treating patients suffering from terminal or life-threatening conditions,” including treatment-resistant mental health conditions.

Though the bill’s text doesn’t list specific conditions, a report from the Senate Health and Human Services Committee mentions depression, anxiety, schizophrenia, bipolar disorder and PTSD as “widespread and affecting millions worldwide and many in the State’s community.”

If passed, the bill would require the Department of Health to submit annual progress reports to the legislature.

Money for the new fund would come either from appropriations by the legislature or from gifts, donations or grants from public agencies or private entities. The bill it its current form earmarks no money for the account.

Last week the plan advanced out of the Senate Health and Human Services Committee, where the chair warned that the plan would need sustainable funding in order to become law.

“This is not gonna pass conference unless you folks come up with a self-sustaining fund,” Sen. Joy San Buenaventura (D) said at the time. “Donations alone is not gonna be able to cut the attorney general’s concerns.”

The proposal has support from a variety of veterans and mental health groups, as well as numerous individual commenters.

Joint testimony from the groups Reason for Hope and the Veteran Mental Health Leadership Coalition, for example, says the legislation “represents a bold and necessary step toward addressing the urgent mental health needs of our Veterans.”

“By establishing this fund, advisory council, and ensuring timely state regulatory alignment, Hawaii can become a national leader in providing access to innovative, life-saving treatments for those who have selflessly served our country,” the organizations said, noting that traditional treatments for conditions such as PSTD and severe forms of depression have not been sufficient for many veterans and first responders.

Separately in Hawaii last week, a pair of Senate panels approved a broad bill that would legalize adult-use marijuana and bring together hemp and cannabis regulation under a single state agency.

If enacted, the legislation would establish the Hawaii Cannabis and Hemp Office, which would oversee adult-use cannabis, medical marijuana and hemp businesses. Adults 21 and older would be able to possess up to an ounce of marijuana and five grams of cannabis concentrate, and they could also grow limited amounts of marijuana at home for personal use.

The joint Senate committee hearing came on the heels of a vote last week by Hawaii’s House of Representatives to delay a companion version of the legalization proposal, effectively halting that bill’s progress until next legislative session. Even if the Senate advances to the House, it will face a tough road to passage in that chamber.

Earlier in the week, a Senate panel approved a proposal to quintuple the amount of marijuana that a person can possess without risk of criminal charges.

The bill, SB 319, would increase the amount of cannabis that’s been decriminalized in Hawaii from the current 3 grams up to 15 grams. Possession of any amount of marijuana up to the 15-gram limit would remain a civil violation, punishable by a fine of $130.

Meanwhile, the House Committee on Labor unanimously voted last month to advance legislation that would protect state-registered medical marijuana patients from discrimination in the workplace.

7 In 10 Pennsylvania Voters—Including A Majority Of Republicans—Support Marijuana Legalization, New Poll Finds

Comments


Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page